Israel Active

Israel’s MetaSight Diagnostics is developing fast, low-cost mass spectrometry to perform vast amounts of serum biopsies of the metabolome (molecules in a cell). These can detect cancer, liver disease, cardiovascular and neurological diseases etc. MetaSight is working with KSM (Maccabi’s R&D).

A 5-year study of patients has proved the success of the focused ultrasound treatment from Israel’s Insightec (see previously). It improved quality of life with no progressive or delayed complications. Insightec's technology has been used 11,000+ times globally.

Israel’s Essence SmartCare (see previously) has won a contract from the Community of Madrid governmental region. Essence will use its digital AI systems to replace outdated analog remote care services for 100,000 senior citizens and disabled individuals.

Israel’s NeuroTrigger is developing a powered muscle stimulator to repeatedly contract muscles to increase their range of motion and prevent retardation. Neurotrigger has received a BIRD grant (see below) to develop an eyelid pacemaker that restores blinking to those with facial paralysis.

MAGENTIQ-COLO from Israel’s MAGENTIQ-EYE (see previously) has been cleared by the US FDA and Israel’s AMAR, and received Europe’s CE Mark. The AI-assisted device is significantly more efficient in detecting adenomas (pre-cancerous polyps).

The US FDA has approved the upgraded 15-minute bacteria vs virus diagnostic blood test device from Israel’s MeMed (see previously). The new MeMed BV is now suitable for urgent care centers, as it avoids the clotting and spinning process of the original.

In a small clinical study, Israeli and UK researchers found non-invasive brain stimulation improved the condition of 55% of unmedicated ADHD children aged 6-12. Only 17% of the placebo control group improved. 64% of the treated children retained the improvement weeks later.

Israel’s Quai.MD is developing an AI- platform that improves hospital patient care, reduces costs and saves doctors’ time. The process is tailored to the patient and hospital. Partners include Mayo Clinic & MUSC. Initial focus is the diagnosis of patients with chest pain.

The U.S. National Institutes of Health has granted Israel’s Pluri (previously Pluristem) $4.2 million to develop its PLX-R18 (see ) as a treatment for Hematopoietic Acute Radiation Syndrome - a deadly disease that can result from nuclear disasters and radiation exposure.

Israel’s ImPact Biotech has received Orphan treatment designation from the US FDA for its Padeliporfin VTP in Pancreatic Cancer. ImPact stands for IMmune Photo Activated Cancer Treatment and VTP is Vascular Targeted Photodynamic therapy.